Clear Harbor Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-27,000
Closed -$130K – 504
2026
Q2
$130K Hold
27,000
– – 0.01% 431
2026
Q1
$122K Sell
27,000
-47,761
-64% -$209K 0.01% 430
2025
Q4
$360K Hold
74,761
– – 0.02% 340
2025
Q3
$339K Sell
74,761
-5,000
-6% -$18.4K 0.02% 339
2025
Q2
$246K Hold
79,761
– – 0.02% 361
2025
Q1
$278K Hold
79,761
– – 0.02% 333
2024
Q4
$261K Buy
79,761
+5,000
+7% +$18.4K 0.02% 328
2024
Q3
$288K Sell
74,761
-26,000
-26% -$100K 0.02% 300
2024
Q2
$311K Sell
100,761
-15,500
-13% -$46.5K 0.03% 287
2024
Q1
$300K Sell
116,261
-23,000
-17% -$59.6K 0.03% 289
2023
Q4
$348K Buy
139,261
+7,500
+6% +$14.7K 0.03% 267
2023
Q3
$267K Buy
131,761
+78,761
+149% +$165K 0.03% 280
2023
Q2
$122K Hold
53,000
– – 0.01% 331
2023
Q1
$161K Hold
53,000
– – 0.02% 348
2022
Q4
$123K Buy
+53,000
New +$127K 0.02% 337

Other funds holding ABUS

Clear Harbor Asset Management's ABUS Position: Q3 2026 in Review

Clear Harbor Asset Management sold out of Arbutus Biopharma (ABUS) in Q3 2026, closing a stake of 27,000 shares — an estimated $130K sold.

Clear Harbor Asset Management first reported a position in ABUS in Q4 2022 and held it in 15 quarters. The position peaked at $360K in Q4 2025. 216 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

  • Clear Harbor Asset Management reported no remaining Arbutus Biopharma position as of Q3 2026 after selling out during the quarter.
  • Clear Harbor Asset Management sold 27,000 Arbutus Biopharma shares in Q3 2026, an estimated $130K.
  • Clear Harbor Asset Management first reported a position in Arbutus Biopharma in Q4 2022 and held it in 15 quarters.
  • Clear Harbor Asset Management's Arbutus Biopharma position peaked at $360K in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on Clear Harbor Asset Management's 13F filing for Q3 2026, filed 5 Nov 2026.